<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288196</url>
  </required_header>
  <id_info>
    <org_study_id>CR017752</org_study_id>
    <secondary_id>CNTO6785OPD1001</secondary_id>
    <nct_id>NCT01288196</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of CNTO 6785 Following a Single Intravenous or a Single Subcutaneous Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen-Cilag International NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen-Cilag International NV</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, blood levels, and immune
      responses of CNTO 6785 after administration to healthy adult volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (study drug will be assigned by chance), double-blind (neither the
      volunteer, physician, or study staff will know the identity of the assigned treatment), study
      to evaluate the safety, tolerability, pharmacokinetics (blood levels of drug) and
      immunogenicity (development of antibodies to the drug) of a single dose of CNTO 6785
      administered to healthy adult volunteers intravenously (in the vein) or by subcutaneous
      (under the skin) administration to healthy adult volunteers.This will be the first
      administration of CNTO 6785 to humans; therefore, no clinical experience is available.
      Healthy volunteers will receive a single dose of 1, 3, or 10 mg/kg of CNTO 6785 or placebo as
      a 30-minute intravenous (IV) (injection into a blood vessel) infusion or a single dose of 3
      mg/kg of CNTO 6785 administered in up to 3 subcutaneous (under the skin) (SC) injections.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and type of adverse events reported</measure>
    <time_frame>Up to Week 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and type of Infusion (injection) site reactions</measure>
    <time_frame>Up to Week 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs measurements</measure>
    <time_frame>Up to Week 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory test results</measure>
    <time_frame>Up to Week 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Findings from cardiology assessments (electrocardiograms [ECGs] and cardiac telemetry)</measure>
    <time_frame>Up to Week 17</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of CNTO 6785</measure>
    <time_frame>Up to Week 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum antibodies to CNTO 6785</measure>
    <time_frame>Up to Week 17</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 6785 1 mg/kg IV A single 30-minute IV infusion of CNTO 6785 1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 6785 3 mg/kg IV A single 30-minute IV infusion of CNTO 6785 3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 6785 10 mg/kg IV A single 30-minute IV infusion of CNTO 6785 10 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>004</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV A single 30-minute IV infusion of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 6785 SC A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>006</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC A single SC dose of placebo administered in up to 3 SC injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV</intervention_name>
    <description>A single 30-minute IV infusion of placebo</description>
    <arm_group_label>004</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTO 6785 1 mg/kg IV</intervention_name>
    <description>A single 30-minute IV infusion of CNTO 6785 1 mg/kg</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTO 6785 3 mg/kg IV</intervention_name>
    <description>A single 30-minute IV infusion of CNTO 6785 3 mg/kg</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTO 6785 10 mg/kg IV</intervention_name>
    <description>A single 30-minute IV infusion of CNTO 6785 10 mg/kg</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTO 6785 SC</intervention_name>
    <description>A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections</description>
    <arm_group_label>005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SC</intervention_name>
    <description>A single SC dose of placebo administered in up to 3 SC injections</description>
    <arm_group_label>006</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult volunteer with no clinically significant abnormalities as determined by
             the investigator (study physician)

          -  Have a body mass index (BMI) between 19-30 kg/m2

          -  Be a non-smoker for at least 6 months prior to study participation

          -  Women must be postmenopausal or surgically sterile

        Exclusion Criteria:

          -  Currently have or have a history of any clinically significant medical illness or
             medical disorders (includes malignancies or serious infections) that the investigator
             (study physician) considers should exclude the volunteer from the study

          -  Major surgery or significant trauma within 12 weeks of screening

          -  Any volunteer who plans to undergo elective surgery within 4 weeks prior to study
             agent administration and through the end of the study

          -  Consumes, on average, more than approximately 500 mg/day of caffeine (as contained in
             5 cups of tea or coffee or 8 cans of soda or other caffeinated products per day).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen-Cilag International NV Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen-Cilag International NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CNTO 6785</keyword>
  <keyword>Intravenous</keyword>
  <keyword>Subcutaneous</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

